ID
45835
Beskrivning
Principal Investigator: James N. Ingle, M.D., Mayo Clinic, Rochester, MN, USA MeSH: Neoplasm,Breast Neoplasms,Neoplasm Metastasis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001043 *Source of patients*:The source of the patients for this genome-wide case-control study was MA.27, which was conducted as a multi-cooperative group effort under the auspices of the NCI Breast Cancer Intergroup of North America. The NCIC Clinical Trials Group (CTG) serves as the coordinating group, with participation by the NCI-sponsored North Central Cancer Treatment Group, Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group, and Cancer and Leukemia Group B (CALGB). MA.27 involved postmenopausal women with histologically confirmed and completely resected invasive breast cancer with surgical margins clear of invasive carcinoma in the following TMN categories (AJCC Version 6): pT1, pT2, pT3; pNx, pN0, pN1, pN2, pN3 (only when the sole basis is presence of 10 or more involved axillary nodes); MO. The primary tumor must have been estrogen receptor (ER) and/or progesterone receptor positive. Patients were stratified by lymph node status at diagnosis, prior adjuvant chemotherapy, and trastuzumab use and were randomized to 5 years of adjuvant therapy with anastrozole or exemestane. The trial was activated on May 26, 2003, and reached its accrual objectives on July 31, 2008, after the randomization of 6827 North American patients, with the majority (79%) providing DNA and consent for genetic testing. Non-North American patients were also entered by the International Breast Cancer Study Group but they did not contribute DNA. From 2003 to December 21, 2004, patients also underwent a second randomization to celecoxib 400 mg twice daily or placebo but, after the entry of 1,622 patients, this treatment was discontinued because of reports of increased cardiovascular risk associated with celecoxib. The final results of this study have been published, see Goss et al., 2013 (23358971). The patients in this analysis came from three cohorts: Cohort 1 consisted of 870 patients genotyped on the Illumina Human610-Quad BeadChip studied in a GWAS with the phenotype of musculoskeletal adverse event, see Ingle et al., 2010 (20876420), Cohort 2 consisted of 882 patients genotyped on the Illumina OmniExpress platform studied in a GWAS with the phenotype of fragility fractures, see Liu et al., 2014 (25148458), and the remaining 2913 patients were genotyped with the Illumina OmniExpressExome platform.
Länk
Nyckelord
Versioner (1)
- 2023-08-07 2023-08-07 - Simon Heim
Rättsinnehavare
James N. Ingle, M.D., Mayo Clinic, Rochester, MN, USA
Uppladdad den
7 augusti 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs001043 GWAS of Breast Events with Adjuvant Aromatase Inhibitors
The dataset provides data about the length of the Breast Cancer Free Interval (BCFI), tumor characteristics prior to resection (e.g. estrogen/progesterone positive, lymph node status, T-/N-stage values, type of treatment used [e.g. adjuvant anastrozole or exemestane, celocoxib, herceptin, bisphonate]), bone frailty, MSK (musculoskeletal) event and basic sociodemographic data, including self-reported and genotype-based race data.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (Cases defined as patients with BCFI event - Controls defined as patients without BCFI event).
- Subject - Sample Mapping - Sample Use Information
- The dataset provides data about the length of the Breast Cancer Free Interval (BCFI), tumor characteristics prior to resection (e.g. estrogen/progesterone positive, lymph node status, T-/N-stage values, type of treatment used [e.g. adjuvant anastrozole or exemestane, celocoxib, herceptin, bisphonate]), bone frailty, MSK (musculoskeletal) event and basic sociodemographic data, including self-reported and genotype-based race data.
- Sample - Attribute Information
Similar models
The dataset provides data about the length of the Breast Cancer Free Interval (BCFI), tumor characteristics prior to resection (e.g. estrogen/progesterone positive, lymph node status, T-/N-stage values, type of treatment used [e.g. adjuvant anastrozole or exemestane, celocoxib, herceptin, bisphonate]), bone frailty, MSK (musculoskeletal) event and basic sociodemographic data, including self-reported and genotype-based race data.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (Cases defined as patients with BCFI event - Controls defined as patients without BCFI event).
- Subject - Sample Mapping - Sample Use Information
- The dataset provides data about the length of the Breast Cancer Free Interval (BCFI), tumor characteristics prior to resection (e.g. estrogen/progesterone positive, lymph node status, T-/N-stage values, type of treatment used [e.g. adjuvant anastrozole or exemestane, celocoxib, herceptin, bisphonate]), bone frailty, MSK (musculoskeletal) event and basic sociodemographic data, including self-reported and genotype-based race data.
- Sample - Attribute Information
C0016658 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,2])
C0599755 (UMLS CUI [1,3])
C4698957 (UMLS CUI [1,2])
C0042153 (UMLS CUI [1,2])
C0042153 (UMLS CUI [1,2])
C0042153 (UMLS CUI [1,2])
C1442488 (UMLS CUI [1,2])
C1442880 (UMLS CUI [1,3])
C0034656 (UMLS CUI [1,2])
C1442880 (UMLS CUI [1,3])
C0444921 (UMLS CUI [1,2])
C2267018 (UMLS CUI [1,2])
C0038953 (UMLS CUI [1,2])
C5420137 (UMLS CUI [1,3])
C0034656 (UMLS CUI [1,2])
C1706256 (UMLS CUI [1,3])
C0441471 (UMLS CUI [1,4])
C0332168 (UMLS CUI [2,1])
C0034656 (UMLS CUI [2,2])
C5239465 (UMLS CUI [2,3])
C0009932 (UMLS CUI [2,4])
C0441471 (UMLS CUI [1,2])
C1706256 (UMLS CUI [1,3])
Inga kommentarer